Public awareness of the link between drinking alcohol and an elevated risk of cancer has grown since last fall, with more than half of Americans now saying that regularly consuming alcohol increases your chances of later ...
Apr 1, 2025
0
0
Despite decades of research to develop effective treatments, the median survival for glioblastoma—the most common malignant primary brain tumor in adults—is just 15–18 months after diagnosis. One reason for this grim ...
Apr 1, 2025
0
1
Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually. Unfortunately, many cases are detected at advanced stages due to the lack of clear early symptoms, ...
Apr 1, 2025
0
0
Scientists have revealed exactly how tobacco smoke damages DNA to drive the development of different types of head and neck cancer, a finding that could unlock new treatments and prevention strategies.
Mar 31, 2025
0
33
When your social media account starts spewing out nonsensical or threatening status updates, it's safe to assume that it has been hacked and must be shut down.
Mar 31, 2025
0
71
Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, according to a study published in Advanced Science.
Mar 31, 2025
0
12
University of Huddersfield scientist, Dr. Anke Brüning-Richardson, has published promising findings from the past seven years of research into a new approach for the treatment of highly aggressive brain tumors.
Mar 31, 2025
0
0
Researchers from the Faculty of Physics and the Life Sciences Center of Vilnius University (VU), with co-authors from Harvard University, the University of Toronto, National Cancer Institute and "Light Conversion," have developed ...
Mar 31, 2025
0
0
During development, cells grow, expand, and migrate to generate tissues and organs in a highly controlled manner. Many intracellular pathways—series of signaling cascades within a cell—regulate these actions to avoid ...
Mar 31, 2025
0
0
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new standard of care for this ...
Mar 31, 2025
0
0
